JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYB – Research Report) today and set a price target of $36.00. The company’s shares opened today at $13.53.
Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -7.9% and a 36.03% success rate on recommended stocks.
Rallybio has an analyst consensus of Moderate Buy, with a price target consensus of $36.00.
See today’s best-performing stocks on TipRanks >>
Based on Rallybio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.58 million. In comparison, last year the company had a GAAP net loss of $11.13 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.